Allurion Technologies, Inc. (OTCQB:ALUR), a pioneer in metabolically healthy weight loss, today announced a 1-for-15 reverse stock of its outstanding common stock intended to support regaining compliance with the
Allurion Technologies, Inc. (OTCQB:ALUR), a pioneer in metabolically healthy weight loss, today announced successful early traction in the launch of the Allurion Program in the United States, marked by strong clinical
Company's recent FDA approval catalyzes plan to regain compliance with listing requirements of NYSE or another exchange; shares of common stock expected to continue trading on NYSE during appeal process
Allurion
Allurion Technologies, Inc. (NYSE:ALUR) (the "Company" or "Allurion"), a pioneer in metabolically healthy weight loss, today announced the entry into a definitive agreement for the immediate exercise of certain
Approval provides Allurion with access to approximately 80 million Americans with obesity
Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that the U.S. Food and
Through Bionut, a leader in obesity care in Argentina, Allurion Program patients will now have access to discounted Mounjaro to be used in combination with the Allurion Smart Capsule
Allurion Technologies, Inc.
Strong quarter-over-quarter revenue growth with continued, substantial improvement in operating expenses and operating loss
Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss,
Average Total Weight Loss of 23% With 14% Increase in Lean Body Mass After 12 Months
All patients remained adherent to tirzepatide for the duration of the study
Allurion Technologies, Inc. ("Allurion" or the
Case-controlled study in 1,143 patients demonstrates superior weight reduction, fat mass loss, and visceral fat loss with the Allurion Smart Capsule combined with lifestyle intervention compared to lifestyle
Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with ProSurg Medical, a leading Brazilian medical device company specializing
Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its financial results for the third quarter and provided a business update.
Recent Company
Passing of key audits with zero findings and completion of Day-100 meeting are significant milestones in the FDA PMA process as the Company enters final stages of FDA review process for its Allurion Smart
Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the third quarter 2025 on Wednesday,
Multicenter study across six countries demonstrates safety and efficacy of two consecutive treatments in adults with obesity
Weight loss of greater than 20% on par with bariatric surgery and high dose GLP-1
Allurion Technologies, Inc. (NYSE:ALUR), a pioneer in metabolically healthy weight loss, today announced its participation in the ROTH 4th Annual Healthcare Opportunities Conference, which will be held on October 9,
